// App-Quantinova.ai

428 : Hypermethylation of GATA2 is validated as a marker of progression in non-muscle invasive bladder cancer

Researchers

Presenter

  • Kim E.M. van Kessel

Principal Investigators

  • Kirstin A. van der Keur

  • Lars Dyrskjt

  • Ferran Algaba

  • Naeromy Welvaart

  • Willemien Beukers

  • Ulrika Segersten

  • Bastian Keck

  • Tobias Maurer

  • Tatjana Simic

  • Marcus Horstmann

  • Joost L. Boormans

  • Francisco X. Real

  • Nuria Malats

  • Per-Uno Malmstrom

  • Torben F. rntoft

  • Ellen C. Zwarthoff

Medical Centers

  • Erasmus MC, Rotterdam, Netherlands

  • Aarhus University Hospital, Aarhus, Denmark

  • Universitat Autonoma de Barcelona-Spain, Barcelona, Spain

  • Uppsala University Hospital, Uppsala, Sweden

  • Friedrich Alexander University Erlangen-Nurnberg, Nurnberg, Germany

  • Klinikum rechts der Isar, Technical University Munich, Munich, Germany

  • University of Belgrade, Serbia., Belgrade, Serbia

  • Friedrich-Schiller-University Jena, Jena, Germany

  • CNIO - Spanish National Cancer Research Center, Madrid, Spain

Locations

  • Netherlands

  • Spain

  • Germany

  • Serbia

  • Denmark

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Fibroblast growth factor receptor 3

  • GATA-binding protein 2

  • T-box 2

  • Telomerase reverse transcriptase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved